Tag: 100-200

On May 17, 2018, Na, Yun Soo; Bang, Keuk Chan; Park, Joon Seok published a patent.Product Details of 16230-24-3 The title of the patent was Preparation of novel pyrrolopyrimidine derivatives as BTK inhibitors and pharmaceutical composition comprising the same. And the patent contained the following:

The invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, and the compound according to the invention can be usefully used for the prevention or treatment of diseases in which the BTK inhibitory action is beneficial. Compounds of formula I wherein X is NH and O; L is a bod and CO; R is H, (un)substituted C6-10 aryl and (un)substituted C3-10 heteroaryl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their BTK inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 20.9 n< and 100 % inhibition at 1 μM. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Product Details of 16230-24-3

The Article related to pyrrolopyrimidine preparation btk inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On August 14, 2014, Haq, Nadia; Niu, Deqiang; Petter, Russell C.; Qiao, Lixin; Singh, Juswinder; Zhu, Zhendong published a patent.Quality Control of N-(3-Aminophenyl)acrylamide The title of the patent was Pyrimidine derivatives as ERK inhibitors and their preparation. And the patent contained the following:

The invention provides compounds of formula I, compositions thereof, and methods of using the same. Compounds of formula I wherein A is (un)substituted Ph, 3- to 8-membered (un)saturated monocyclic ring, 4- to 7-membered monocyclic heterocyclic ring, etc.; B is (un)substituted Ph, (un)substituted (un)saturated 3- to 7-membered carbocyclic ring, 5- to 6-membered monocyclic heteroaryl, absent, etc.; m and p are independently 0 – 4; R1 is a warhead group, wherein R1 is attached to an atom adjacent to where W is attached; each R2 is H, (un)substituted C1-6 aliphatic, halo and OH and derivatives; each R3 is H, halo, OH and derivatives, SH and derivatives, CN, etc.; R4 is H, (un)substituted C1-6 aliphatic, halo, haloalkyl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their ERK inhibitor activity (some data given). The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Quality Control of N-(3-Aminophenyl)acrylamide

The Article related to pyrimidine preparation erk inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of N-(3-Aminophenyl)acrylamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On July 15, 2021, Brown, Trevor N. published an article.Recommanded Product: 685-91-6 The title of the article was Empirical regressions between system parameters and solute descriptors of polyparameter linear free energy relationships (PPLFERs) for predicting solvent-air partitioning. And the article contained the following:

Polyparameter Linear Free Energy Relationships (PPLFERs) are an empirical tool used to predict the equilibrium partitioning of solutes between two phases, referred to as a system. There are exptl. determined solute descriptors for thousands of chems., but there are only on the order of 100 systems with calibrated system parameters, the majority of which are solvents and environmental matrixes in equilibrium with air or water. The goal of this work is to create empirical regressions which use the much more numerous solute descriptors to predict the system parameters of systems which have not yet been calibrated due to a lack of partitioning data. The special case of liquid solvents in equilibrium with air is the focus of this work because this is the case in which the relationship between solute and solvent properties is most clear. First a consistent dataset of PPLFER equations was compiled using partition coefficient data from the literature to recalibrate equations for solvent-air partitioning into the Goss form (Goss, K.-U. 2005) for 89 solvents including water. All 89 solvents have also solute descriptors available in a database curated for this work which describe their behavior as solutes. The pool of descriptors drawn from to create the empirical regressions were the solute descriptors of the solvents normalized to McGowan volume (V), along with interaction parameters between the normalized descriptors. An applicability domain (AD) for the empirical regressions was defined using leverage to measure similarity to the training dataset of solvents, and solvents in the AD typically had lower RMSE for predictions. Some of the empirical regressions for the six system parameters have good predictive power (s, a, b, c) while others are only adequate (v, l). However, when these equations are combined to predict partition coefficients there is a significant cancellation of error and when predicting partition coefficients in an external validation dataset the RMSE is in the range 0.30-0.35. The empirical regressions combined with the PPLFER equations and solvent d. can also be used to predict vapor pressures as an addnl. external validation. Predictions for a dataset of vapor pressures from the literature had an RMSE of 0.26-0.75. Analyzing and comparing the results from these two external validation datasets the RMSE for predicting datasets of partition coefficients for arbitrary solutes in arbitrary systems of solvents in equilibrium with air is estimated to be 0.66 on average The experimental process involved the reaction of N,N-Diethylacetamide(cas: 685-91-6).Recommanded Product: 685-91-6

The Article related to solvent air partitioning regression system parameter solute descriptor pplfer, Phase Equilibriums, Chemical Equilibriums, and Solutions: Partition, Extraction and other aspects.Recommanded Product: 685-91-6

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On January 31, 2020, Canner, Adam J.; Harwood, Laurence M.; Cowell, Joseph; Babra, Jasraj S.; Brown, Solomon F.; Ogden, Mark D. published an article.SDS of cas: 685-91-6 The title of the article was Spectrophotometric Analysis of Ternary Uranyl Systems to Replace Tri-N-butyl Phosphate (TBP) in Used Fuel Reprocessing. And the article contained the following:

In this report, the interaction of monoamide/diamide and monoamide/diglycolamide mixtures with UO2+2 are investigated in pH = 1 methanolic nitric acid media. These monoamides include N,N-dimethylacetamide (DMAA), N,N-diethylacetamide (DEAA), N,N-dibutylacetamide (DBAA) and N,N-dibutylbutanamide (DBBA). N,N,N’N’-tetraethylmalonamide (TEMA) and N,N,N’,N’-tetraethyldiglycolamide (TEDGA), which were chosen as model diamides and diglycolamides, resp. Complex stability constants for each ligand were modeled using the Stability Quotients Using Absorbance Data program using UV-visible data. Complex stoichiometry of ligand mixtures was determined using Job plots and UV-Vis spectrometry. Monoamides were confirmed to produce only disolvate complexes with UO2+2 in solution The log10(K) values for monoamides were found to be independent of amine-side chain length, but were slightly dependent on the carbonyl-side chain length. TEDGA was found to produce multiple uranyl complexes in solution Job plot data indicated that the uranyl cation strongly prefers to bond either only with the monoamide or diamide in ternary monoamide-diamide-UO2 systems. Monoamide-diglycolamide-UO2 systems were more complicated, with Job plot data indicating the potential for multiple ternary species being present is dependent on the monoamide structure. The experimental process involved the reaction of N,N-Diethylacetamide(cas: 685-91-6).SDS of cas: 685-91-6

The Article related to trinbutyl phosphate ternary uranyl system fuel reprocessing, Phase Equilibriums, Chemical Equilibriums, and Solutions: Partition, Extraction and other aspects.SDS of cas: 685-91-6

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On May 31, 2018, Urut, Gulsiye Ozturk; Aydin, Seher; Topkaya, Derya; Sahin, Elif; Alp, Serap published an article.COA of Formula: C10H11NO3 The title of the article was Synthesis, Spectroscopic Characterization and Polymerization Abilities of Blue and Green Light Emitting Oxazol-5-one Fluorophores. And the article contained the following:

New fluorescent thiophenyl group containing oxazol-5-one fluorophores of 3a (4-(3-thiophenylmethylene)-2-phenyloxazol-5-one), 3b (4-(3-thiophenylmethylene)-2-(4-tolyl)oxazol-5-one) and 3c (4-(3-thiophenylmethylene)-2-(4-nitrophenyl)oxazol-5-one) were synthesized and characterized. The newly synthesized oxazol-5-ones absorption and fluorescence characteristics were studied in some solvents of varying polarities. The heterocyclic chromophores were fluorescent, with two of them, 3a and 3b, emitting blue light, while the other one, 3c, emitting green light. The emission maxima of the derivatives varied between 415 and 572 nm according as the extent of conjugation and solvent polarity. As solvent polarity increased, 3c derivatives emission spectra displayed a large bathochromic shift, which revealed the considerable change of the dipole moment of the fluorescent structure because of an intramol. charge transfer interaction. Furthermore, oxazolones polymerization ability via the thiophenyl group linked to the oxazol-5-one heterocycle showed that copolymerization of 3a was achieved, but homopolymerization was not observed The experimental process involved the reaction of 2-(4-Methylbenzamido)acetic acid(cas: 27115-50-0).COA of Formula: C10H11NO3

The Article related to fluorophore green light emitting polymerization ability oxazolone, copolymer, fluorescence, homopolymer, oxazol-5-one, thiophenes, Chemistry of Synthetic High Polymers: Ring-Opening and Other Polymerizations and other aspects.COA of Formula: C10H11NO3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On May 4, 2017, Xu, Xuenong published a patent.Related Products of 16230-24-3 The title of the patent was Process for preparation of Rociletinib. And the patent contained the following:

This invention discloses a process for the preparation of Rociletinib, which comprises condensation reaction of 5-trifluoromethyluracil with 4-(4-acetyl-piperazin-1-yl)-2-methoxyaniline to obtain 2-[[4-(4-acetyl-piperazin-1-yl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-pyrimidin-4-one, followed by halogenation to obtain 2-[[4-(4-acetyl-piperazin-1-yl)-2-methoxy phenyl]amino]-5-(trifluoromethyl)-4-halo-pyrimidine, and amination with N-(3-aminophenyl)-2-acrylamide to obtain title product. The process has the advantages of easily available raw materials, simple procedures, low cost, etc. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Related Products of 16230-24-3

The Article related to preparation rociletinib condensation reaction halogenation amination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On December 30, 2015, Xu, Xuenong published a patent.COA of Formula: C9H10N2O The title of the patent was Process for preparation of Rociletinib. And the patent contained the following:

This invention discloses a process for the preparation of Rociletinib, which comprises condensation reaction of 5-trifluoromethyluracil with 4-(4-acetyl-piperazin-1-yl)-2-methoxyaniline to obtain 2-[[4-(4-acetyl-piperazin-1-yl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-pyrimidin-4-one, followed by halogenation to obtain 2-[[4-(4-acetyl-piperazin-1-yl)-2-methoxy phenyl]amino]-5-(trifluoromethyl)-4-halo-pyrimidine, and amination with N-(3-aminophenyl)-2-acrylamide to obtain title product. The process has the advantages of easily available raw materials, simple procedures, low cost, etc. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).COA of Formula: C9H10N2O

The Article related to preparation rociletinib condensation reaction halogenation amination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C9H10N2O

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On October 2, 2018, Yuan, Hong; Li, Si; Zhao, Jingyuan; Wu, Xiangdong; Wang, Xiaoxi; Wang, Nan; Yao, Bingjie; Zhao, Dan; Yao, Yao; Sun, Xiuli; Ma, Xiaodong published a patent.Safety of N-(3-Aminophenyl)acrylamide The title of the patent was Pyrimidine compound, composition and its application in treatment of lymphoma leukemia. And the patent contained the following:

The invention disclosed a kind of pyrimidine derivative, its preparation method and application as Bruton’s tyrosine kinase inhibitor. The claimed pyrimidine derivative is shown in structure I (R = H, Cl, F, or trifluoromethyl; R1 = H, Cl or F; M = amido group). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can inhibiting Bruton’s tyrosine kinase, can be used for treating Burkitt’s lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Safety of N-(3-Aminophenyl)acrylamide

The Article related to pyrimidine derivative preparation brutons tyrosine kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of N-(3-Aminophenyl)acrylamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On February 22, 2017, Ma, Xiaodong; Yu, Haiqing; Song, Anran; Ge, Yang; Song, Zhendong; Huang, Shanshan; Wang, Changyuan; Liu, Kexin published a patent.SDS of cas: 16230-24-3 The title of the patent was Preparation of purine compounds as BTK tyrosine kinase inhibitors for treating large B cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. And the patent contained the following:

The invention relates to purine compounds, isomers or pharmaceutically acceptable salts or hydrates with formula of I, wherein R1 is one of H, methoxy, Me, chloro or fluoro; R2 is morpholine, 1-methylpiperazine, 1-ethylpiperazine, etc. The invention compounds can be used for treating diseases caused by BTK tyrosine kinase, especially disseminated anaplastic large B cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).SDS of cas: 16230-24-3

The Article related to purine preparation btk tyrosine kinase inhibitor lymphoma leukemia, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On September 28, 2018, Zhai, Xin; Zhou, Yuhong; Gong, Ping; Jing, Tongfei; Lei, Hongrui; Guo, Ming; Xing, Lingyun published a patent.Electric Literature of 16230-24-3 The title of the patent was Tetrahydropyrido[4,3-d]pyrimidine derivative useful in treatment of ATX and EGFR related diseases and its preparation. And the patent contained the following:

The invention relates to tetrahydropyrido[4,3-d]pyrimidine derivative of formula I useful in treatment of ATX and EGFR related diseases and its preparation Compounds I, wherein L is O(CH2)m, S(CH2)m, NH(CH2) m, etc.; m is 0-4; P is O, S, NH, etc; R1 is C6-10 aryl or 5-10-membered heteroaryl (containing 1-3 heteroatoms selected from N, O and S); R3 is C1-6 alkyl, C2-6 alkenyl, C3-6 alkenyl amino, C6-10 aryl, etc.; their optical stereoisomers, pharmaceutically acceptable salts, solvates, or prodrug, are claimed. The inventive compound shows high inhibitory activity on ATX and EGFR, and can be applied in the drugs for preventing and/or treating the diseases caused by abnormal expression of ATX and EGFR, especially the drugs for preventing and/or treating fibrosis and cancer. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Electric Literature of 16230-24-3

The Article related to tetrahydropyrido pyrimidine preparation treatment atx egfr disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Electric Literature of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics